Scientists have come up with a new name for experiments that utilize placebos
Trick or treatment
I’m addicted to placebos.
I could quit but it wouldn’t matter.
On my way home from work today I was listening to Placebo..
I thought I was listening to something else, but obviously I was the control group.
Is that placebo working for you?
Well, now that you mention it, no.
My doctor is concerned my hypochondria is getting worse
So he put me on stronger placebos.
I got in trouble for using performance enhancing drugs
I took a placebo before my psychology exam
I was part of a scientific study on the calming effects of listening to the Three Tenors.
I felt great, but was in the control group. It turns out I was listening to Placebo Domingo.
Scientists have known since at least the 1930s that a doctor’s expectations and personal characteristics can significantly influence a patient’s symptom relief. Within research contexts, avoiding these placebo effects is one reason for double blind studies — to keep experimenters from accidentally biasing their results by telegraphing to test subjects what they expect the results of a study to be.
The new study both demonstrates that the placebo effect is transmitted from doctor to patient, and shows how it might work. Researchers randomly assigned undergraduate students to play the role of a patient or a doctor. The “patients” were given a controlled heat stimulus to the forearm, after receiving one of two types of cream from the “doctor.”
Students in the doctor group had previously been conditioned to believe that one of the creams was pain reliever. But in reality both of the two creams that they administered were an identical petroleum jelly-based placebo. And yet, when the doctor actors believed that the cream was a real medication — the researchers even gave the pseudo-medication a name, “thermedol” — the patient actors reported experiencing significantly lower amounts of pain.
As well-documented as the placebo effect is, to see it play out so cleanly surprised the study’s authors themselves. “We did several more studies to convince ourselves it wasn’t just a fluke,” says the study’s primary author, Luke Chang of Dartmouth University. “I’m impressed at how robust the effect seems to be.”
It seems that this damned placebo effect is getting in the way of developing and authorising new psychiatric drugs. It creates a ‘therapeutic bias'(!) and so the experimenters are experimenting with ways of controlling for it in trials, for example ‘SPCD, sequential parallel comparison design’. These are proving to be not (yet) up to the task, sufficient to be acceptable by bodies such as the RDA. The following is from The Placebo Effect Is Hobbling New Psychiatric Drugs
“The FDA’s rejection cast doubt upon the design, still in use in more than a dozen trials, as a weapon against the placebo effect.
That’s big news because the effect, also called the placebo response, has been growing stronger over the years in clinical studies that randomly assign patients to either an active drug or placebo. When the effect is high, it’s hard to know if a drug just isn’t good enough, if there are errors in the data, or if the participants taking the placebo—an inert pill meant to make them believe they’re getting the real thing—fared unusually well because of their expectations.
It’s a testament to the power of our minds to improve our health, at least temporarily. Many factors boost placebo response. “Most people, whether they know it or not, are biased to believe that they will receive the active drug even if they are told that they have a 50 percent chance of getting placebo, and this ‘therapeutic bias’ increases the placebo response,” says John Krystal, the chair of the psychiatric department at the Yale School of Medicine in New Haven, CT.”
What is now emerging as ‘placebo science’ has its roots in an influential 1955 paper entitled ‘The Powerful Placebo’ by Henry K. Beecher which proposed that placebo effects were clinically important. This remains the most commonly-cited placebo reference.
Henry Knowles Beecher (February 4, 1904 – July 25, 1976) was a pioneering American anesthesiologist, medical ethicist, and investigator of the placebo effect at Harvard Medical School, which now, fittingly enough, co-convenes the Program in Placebo Studies & Therapeutic Encounter (PiPS)
with the Beth Israel Deaconess Medical Center.
The prestigious Beecher Prize, named in his honor, is awarded annually by Harvard Medical School to a medical student who has produced exceptional work in the field of medical ethics.
Like the word dirge, placebo has its origin in the Office of the Dead, the cycle of prayers traditionally sung or recited for the repose of the souls of the dead. The traditional liturgical language of the Roman Catholic Church is Latin, and in Latin, the first word of the first antiphon of the vespers service is placebo, “I shall please.” This word is taken from a phrase in the psalm text that is recited after the antiphon, placebo Domino in regione vivorum, ”I shall please the Lord in the land of the living.” The vespers service of the Office of the Dead came to be called placebo in Middle English, and the expression ‘sing placebo’ came to mean “to flatter, be obsequious.” … Placebo eventually came to mean “flatterer” and “sycophant.”
The term entered medical history in the late 18th century, with a few British doctors that can claim to be the originator. For one, there is Alex Sutherland (born before 1730 – died after 1773) a doctor living and practicing in Bath, Summerset, who used the term to describe certain types of doctors keen to prescribe fashionable medicines such as waters with healing power, which he called “placebo” (doctors) in a popular book published in 1763. About the same time, William Cullen (1710 – 1790) from Edinburgh, Scotland, used it for the first time in a textbook, his Clinical Lectures: He gave a patient mustard powder as a remedy noting “… that I did not trust much to it, but I gave it because it is necessary to give a medicine, and as what I call a placebo,” summarizing today’s entire discussion in a single sentence: Placebos are to please the patient and improve symptoms because of that – what we call the placebo effect. And the third gentleman is John Coakley Lettsom (1744-1815), a doctor from London who resumed a similar position to Cullen; they used placebos of ineffective doses of what were popular medicines of their time.
More on this fascinating history, including the inclusion of placebo in the earliest forms of homeopathic practice, here.
We all know about the ‘nocebo’ effect by now – the dark twin of the beneficial placebo effect. For example, a study showed that the pharmacological efficacy of remifentanil (a pain medication) was significantly decreased after patients were told the infusion was stopped during a heat-pain modulation test. Although the infusion had not actually been halted, participants experienced a significant exacerbation of pain even while still receiving remifentanil.
To counter undesirable ‘nocebo’ effects, this article suggests to health practitioners that ‘pragmatic strategies related to patient–practitioner interaction, clinical setting, and context may be implemented to help minimize and prevent the consolidation of negative expectations’.
There is some evidence – for example, in this study – that simply receiving the results of DNA tests can have a physical impact. Why? Well, once more the Placebo Effect is mentioned (as well as its dark twin, the Nocebo Effect, also covered on this website.
DNA tests are becoming quicker, cheaper and more reliable, so this is an issue we’ll hear more about.
Pain is something of a mystery. While we all experience it, and experience it in degrees, there’s no ‘gold standard’ for estimating the degree of pain. It seems to be a ‘subjective’ experience. In some of the research literature, such as this study, the placebo effect is given a credible place in the landscape of pain and pain management.
“Placebo effects that arise from patients’ positive expectancies and the underlying endogenous modulatory mechanisms may in part account for the variability in pain experience and severity, adherence to treatment, distinct coping strategies, and chronicity. Expectancy-induced analgesia and placebo effects in general have emerged as useful models to assess individual endogenous pain modulatory systems.”
Meantime, in the category of ‘Out There But Maybe Not As Out There As You Might Think’ virtual reality may have the capacity to harness the placebo effect in pain management.
“Recently, Cedars-Sinai also published research on the clinical utility of a virtual reality intervention in the Inpatient setting. The results of the study were overwhelmingly positive with most patients receiving pain and stress relief from the VR experience.”
More on VR applications here.